GlassScriptPhysician profile
Jonah Mcintyre
NPI 1699752303
$1,668.67
in general payments reported to CMS, 2019-2025
31 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $16.37 · 2021: $44.40 · 2022: $343 · 2023: $305 · 2024: $354 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $229.94 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $181.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $122.08 | 2023-2024 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $120.82 | 2022-2025 | Farxiga, Lokelma, Breztri |
| Silk Road Medical, INC. | $110.67 | 2019 | |
| Merck Sharp & Dohme LLC | $96.61 | 2019-2023 | Verquvo, Belsomra |
| Pfizer INC. | $83.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $71.16 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.58 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.02 | 2023-2024 | Xifaxan, Trulance |
| Allergan, INC. | $54.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.26 | 2022 | |
| Harmony Biosciences LLC | $39.26 | 2024 | |
| Avanir Pharmaceuticals, INC. | $38.17 | 2022 | |
| Biogen, INC. | $31.56 | 2025 | Leqembi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atland Pharmaceuticals, LLC | $31.33 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Dexcom, INC. | $30.66 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $29.58 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $26.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.80 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $21.84 | 2025 | |
| Ardelyx, INC. | $20.69 | 2024 | Ibsrela |
| Amgen INC. | $18.60 | 2024 | Otezla, Repatha |
| Shield Therapeutics INC | $18.40 | 2025 | |
| Sumitomo Pharma America, INC. | $18.33 | 2024 | Gemtesa |
| Hologic INC | $15.46 | 2022 | |
| Esperion Therapeutics, INC. | $15.07 | 2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.82 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.77 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.41 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonah Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.